학술논문
Preclinical safety demonstration of the human recombinant erythropoietin HEBERITRO.
Document Type
Article
Author
Source
Subject
*ERYTHROPOIETIN
*COLONY-stimulating factors (Physiology)
*HEMATOPOIETIC growth factors
*BONE marrow
*ERYTHROCYTES
*
*
*
*
Language
ISSN
0864-4551
Abstract
The article presents a study which discussed the preclinical safety demonstration of the human recombinant erythropoietin (EPO) HEBERITRO. EPO is considered as an essential growth factor for erythroid progenitors at the bone marrow that regulates the production of erythrocytes in response to the physiological oxygen demand. The results of the preclinical studies of HEBERITRO show that it is not a toxic agent and does not induce local reactions at the site of administration.